ArticleCardio-oncology (London, England)2026
Enhanced predictive value of post-treatment lymphocyte-based immunoinflammatory biomarkers for cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCancer therapy–related cardiac dysfunction (CTRCD) is a major cardiovascular complication in breast cancer patients receiving anthracycline-based chemotherapy, with the systemic inflammatory response playing a pivotal role in its pathogenesis. The association between lymphocyte-based immunoinflammatory biomarkers and CTRCD remains incompletely elucidated, particularly regarding the predictive value of dynamic changes in these indices. This study aimed to investigate the predictive value of lymphocyte-based immunoinflammatory biomarkers for CTRCD in breast cancer patients undergoing anthracycline treatment.
methodsWe retrospectively collected clinical data from breast cancer patients treated with anthracycline-based chemotherapy and conducted follow-up to monitor the development of CTRCD. Routine blood tests were performed pre- and post-anthracycline therapy, and seven lymphocyte-based immunoinflammatory indices (NLR, MLR, NMLR, SIRI, PLR, SII, PIV) were calculated accordingly. Receiver operating characteristic (ROC) curve analysis was used to compare the predictive value of these indices for CTRCD, while Kaplan-Meier curves and Cox regression analysis were performed for survival and risk factor assessment.
resultsA total of 75 patients were enrolled and followed up for a median of 27 months, with CTRCD observed in 9 (12%) cases. Lymphocyte-based immunoinflammatory biomarker levels were significantly elevated after anthracycline therapy. ROC curve analysis showed that post-treatment immunoinflammatory biomarkers had significantly higher predictive value for CTRCD than pre-treatment indices, with the AUCs of post-treatment MLR, NMLR, SIRI, SII, and PIV were 0.812, 0.828, 0.889, 0.803, 0.854 respectively. Additionally, post-treatment MLR, NMLR, SIRI, SII and PIV correlated significantly and positively with LVEF reduction at the 12th month, with correlation coefficients (r values) of 0.517 (P < 0.001), 0.552 (P < 0.001), 0.594 (P < 0.001), 0.415 (P < 0.001) and 0.559 (P < 0.001), respectively. Kaplan-Meier survival analysis revealed that patients with elevated post-treatment levels of these indices had a significantly increased risk of CTRCD. Multivariate Cox regression analysis further confirmed that post-treatment MLR (HR = 18.747, 95% CI = 1.871-187.799, p = 0.013), SIRI (HR = 2.877, 95% CI = 1.243–6.659, p = 0.014), and PIV (HR = 1.007, 95% CI = 1.002–1.012, p = 0.011) were independent predictors of CTRCD.
conclusionLymphocyte-based immunoinflammatory biomarkers assessed post-anthracycline therapy exhibit robust predictive value for CTRCD, with MLR, SIRI, and PIV serving as independent predictors of CTRCD in breast cancer patients receiving anthracycline-based chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.